1)Roach M 3rd, Hanks G, Thames H Jr, et al:Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
2)Stock RG, Stone NN and Cesaretti JA:Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer:descriptions and implications. Int J Radiat Oncol Biol Phys 56:448-453, 2003
3)Toledano A, Chauveinc L, Flam T, et al:PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure:a study of 295 patients with a minimum 3-year followup. Brachytherapy 5:122-126, 2006
4)Satoh T, Ishiyama H, Matsumoto K, et al:Prostate-specific antigen“bounce”after permanent 125I-implant brachytherapy in Japanese men:a multi-institutional pooled analysis. BJU Int 103:1064-1068, 2009
5)Kotzerke J, Volkmer BG, Neumaier B, et al:Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29:1380-1384, 2002
6)Agarwal PK, Sadetsky N, Konety BR, et al:Treatment failure after primary and salvage therapy for prostate cancer:likelihood, patterns of care, and outcomes. Cancer 112:307-314, 2008
7)Shipley WU, Desilvio M, Pilepich MV, et al:Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer:a secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162-1167, 2006
8)Pinover WH, Horwitz EM, Hanlon AL, et al:Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97:1127-1133, 2003
9)Alongi F, De Bari B, Campostrini F, et al:Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer:a review. Crit Rev Oncol Hematol. 2013 Aug
10)Murat FJ, Poissonnier L, Rabilloud M, et al:Mid-term results demonstrate salvage high-intensity focused ultrasound(HIFU)as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55:640-647, 2009